Tagged with B

Shire Brazil Minister Pimentel recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry here in Brazil? First of all, the government must keep the status quo to respect intellectual property. This is imperative,…

ITF-Labomed Labomed was bought by Italfarmaco in 2009, but aside from that, what have been the main milestones and achievements of Labomed since its creation in 1968? When I came to Labomed in 1997, I began a process of renewing the company’s product portfolio and changing the overall profile of Labomed.…

Bristol-Myers Squibb France BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France and what it means for the future? In the larger context of the industry, we are at a crossroads where…

Meizler Biopharma There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re second generation, of course! I am an architect by training. Before entering the pharmaceutical industry I owned an engineering and…

GlaxoSmithKline Colombia Michael Sean Reilly: General Manager for Pharmaceuticals Juan Carlos Berbessi: Medical Director Maria del Pilar Rubio: Medical Manager for Vaccines Gustavo Zapata: Finance Director Juan Pablo Restrepo: Legal Affairs Manager What is the strategic role and importance of Colombia within the larger global framework of GlaxoSmithKline (GSK)? Michael Sean Reilly:…

Novo Nordisk Brazil Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is a tendency for its sudden prevalence to result in less-than-adequate treatment profiles. What have you observed here in Brazil? The…

GSK Brazil You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you along that trajectory, and what have been some of the most important milestones since your arrival here in 2008? I…

Bausch & Lomb Poland BAUSCH + LOMB has over 150 years of heritage and has always been associated with optics and ophthalmology. Therefore the company has been able to build a very strong brand image throughout the years and is today recognized as the best in eye health. Would you say it is an…

Farmindustria & Laboratorio Volta As the CEO of Farmindustria since 1998, what would you say has been your recipe for the impressive success that the company has experienced, considering that Farmindustria represents 35% of all contract manufacturing activities in Chile? Our strongest key to success has certainly been the team that work’s here. Manufacturing…

IMS Health Brazil We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a coherent story explaining the evolution since that time in the country’s pharmaceutical history? The one major factor influencing country growth…

Shire Brazil We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there a different approach required in the specific area of HGT? For HGT, one very important element is the basic regulatory…

Baxter Chile Baxter Chile established itself in the country through the acquisition of a local manufacturer in 1995. What have been the main challenges for the company as a local manufacturer? Chile is a market with many opportunities. For Baxter in Chile, our biggest challenge is maintaining a competitive pricing strategy while…